<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941025-2-00069</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> November 3, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=3 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=3 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=3 -->  <RINDOCK>[Docket No. 94N&hyph;0202]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=3 --> SmithKline Beecham Animal Health, et al.; Withdrawal of Approval of NADA's <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is withdrawing approval of three new animal drug applications (NADA's) and those portions of a fourth NADA providing for the use of nitrofurazone solution drug products. This action is being taken at the written request of the sponsors. In a final rule published elsewhere in this issue of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> , FDA is amending the regulations by removing the entries which reflect approval of the NADA's. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> November 3, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Mohammad I. Sharar, Center for Veterinary Medicine (HFV&hyph;216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;0749. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA is withdrawing approval of three NADA's and those portions of a fourth NADA (6&hyph;475) providing for the use of nitrofurazone solution drug products. The NADA's are:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 2,L1,nj,i1,s15,20C -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Sponsor  <!-- PJG 007 0150 intable --> 1NADA No. <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=01 g=1 f=1 --> SmithKline Beecham Animal Health, 1600 Paoli Pike, West Chester, PA 19380  <!-- PJG 007 0104 intable --> 6&hyph;475  <!-- PJG 0012 frnewline --> Veterinary Laboratories, Inc., 12340 Santa Fe Dr., Lenexa, KS 66215  <!-- PJG 007 0104 intable --> 121&hyph;559 <!-- PJG 0012 frnewline --> Fermenta Animal Health Co., 10150 North Executive Hills Blvd., Kansas City, MO 64153  <!-- PJG 007 0104 intable --> 126&hyph;023 <!-- PJG 0012 frnewline --> Med-Pharmex, Inc., Biomed Laboratories, 325 East Arrow Hwy., San Dimas, CA 91773  <!-- PJG 007 0104 intable --> 126&hyph;950 <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The NADA's provide for over-the-counter use of 0.2 percent nitrofurazone solution on dogs, cats, and horses for prevention or treatment of topical bacterial infections, and prescription use for female equine genital tract infections and impaired fertility due to strains of certain bacteria. <!-- PJG 0012 frnewline --> One of the requirements of the Federal Food, Drug, and Cosmetic Act for receiving approval of a new animal drug is that the conditions of use prescribed, recommended, or suggested in the proposed labeling are reasonably certain to be followed in practice (21 U.S.C. 360b (c)(2)). New information has established that the labeled directions for use of the nitrofurazone solution products have not been followed in practice. When FDA informed the products' sponsors of this situation, they requested voluntary withdrawal of approval of their applications. By so doing they have waived their right to a hearing. <!-- PJG 0012 frnewline --> The withdrawals of approval are effective November 3, 1994. All manufacturing of the products must cease on this date. FDA, however, will exercise its enforcement discretion and will not take regulatory action, based on lack of approval, against the subject products if distributed from sponsor-owned facilities through December 31, 1994, and used before their expiration date. <!-- PJG 0012 frnewline --> Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with &sect;514.115  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Withdrawal of approval of applications <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (21 CFR 514.115), notice is given that approval of NADA's 121&hyph;559, 126&hyph;023, and 126&hyph;950 and those portions of NADA 6&hyph;475 providing for the use of nitrofurazone solution drug products and all supplements and amendments thereto is hereby withdrawn, effective November 3, 1994. This withdrawal of approval does not affect the nitrofurazone-containing ointment and soluble powder products covered by NADA 6&hyph;475. <!-- PJG 0012 frnewline --> In a final rule published elsewhere in the issue of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , FDA is removing and reserving &sect;524.1580d which reflects the approval of the NADA's. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: September 21, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Stephen F. Sundlof, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Director, Center for Veterinary Medicine. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;26377 Filed 10&hyph;24&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            